RxDoctor Payments Data

Juanita Kreiser, DO

Internal Medicine · Harrisburg, PANPI 1760615447

Payments from drug & device makers

$858in general payments, 2019–2025

Across 51 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$103
  • Novo Nordisk$102
  • Lilly USA, LLC$80
  • Astellas Pharma US Inc$73
  • Johnson & Johnson$62
  • Merck$61
  • plus $377 from 14 others

What the payments were for

  • Food & beverage$858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$858 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$250,646
Medicare patients
194
Services billed
2,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban292$160,825
JardianceEmpagliflozin52$29,344
EntrestoSacubitril/Valsartan44$28,870
JanuviaSitagliptin Phosphate55$28,065
MyrbetriqMirabegron40$18,779
OzempicSemaglutide11$10,931
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,852
TradjentaLinagliptin22$8,106
XareltoRivaroxaban15$7,675
Incruse ElliptaUmeclidinium Bromide20$7,428
Atorvastatin Calcium407$7,221
Spiriva RespimatTiotropium Bromide11$6,025
Spiriva HandihalerTiotropium Bromide11$5,936
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$5,693
Pantoprazole Sodium317$4,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$160,825292 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$53$43,47685 claims
MerckJanuvia, Janumet$61$31,11266 claims
NovartisEntresto$15$28,87044 claims
Astellas Pharma US IncMyrbetriq$73$18,77940 claims
GSKTrelegy Ellipta, Incruse Ellipta$43$16,28033 claims
Novo NordiskOzempic$102$10,93111 claims
Johnson & JohnsonXarelto$62$7,67515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Harrisburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →